{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:12:11Z","timestamp":1791159131092,"version":"4.1.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T00:00:00Z","timestamp":1273708800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Multiple myeloma (MM) is characterized by a strong dependence of the tumor cells on their microenvironment, which produces growth factors supporting survival and proliferation of myeloma cells (MMC). In the past few years, many myeloma growth factors (MGF) have been described in the literature. However, their relative importance and the nature of the cells producing MGF remain unidentified for many of them.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We have analysed the expression of 51 MGF and 36 MGF receptors (MGFR) using Affymetrix microarrays throughout normal plasma cell differentiation, in MMC and in cells from the bone marrow (BM) microenvironment (CD14, CD3, polymorphonuclear neutrophils, stromal cells and osteoclasts).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>4\/51 MGF and 9\/36 MGF-receptors genes were significantly overexpressed in plasmablasts (PPC) and BM plasma cell (BMPC) compared to B cells whereas 11 MGF and 11 MGFR genes were overexpressed in BMPC compared to PPC. 3 MGF genes (AREG, NRG3, Wnt5A) and none of the receptors were significantly overexpressed in MMC versus BMPC. Furthermore, 3\/51 MGF genes were overexpressed in MMC compared to the the BM microenvironment whereas 22\/51 MGF genes were overexpressed in one environment subpopulation compared to MMC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Two major messages arise from this analysis 1) The majority of MGF genes is expressed by the bone marrow environment. 2) Several MGF and their receptors are overexpressed throughout normal plasma cell differentiation. This study provides an extensive and comparative analysis of MGF expression in plasma cell differentiation and in MM and gives new insights in the understanding of intercellular communication signals in MM.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-10-198","type":"journal-article","created":{"date-parts":[[2010,5,13]],"date-time":"2010-05-13T19:23:16Z","timestamp":1273778596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays"],"prefix":"10.1186","volume":"10","author":[{"given":"Kar\u00e8ne","family":"Mahtouk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Moreaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"R\u00e8me","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Mei\u00dfner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jourdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Fran\u00e7ois","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T","family":"Pals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,13]]},"reference":[{"issue":"26","key":"1997_CR1","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa032290","volume":"349","author":"M Attal","year":"2003","unstructured":"Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, Monconduit M, Hulin C, Caillot D, Bouabdallah R, Voillat L, Sotto JJ, Grosbois B, Bataille R: Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003, 349 (26): 2495-2502. 10.1056\/NEJMoa032290.","journal-title":"N Engl J Med"},{"issue":"4","key":"1997_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.beha.2005.01.006","volume":"18","author":"MJ Higgins","year":"2005","unstructured":"Higgins MJ, Fonseca R: Genetics of multiple myeloma. Best Pract Res Clin Haematol. 2005, 18 (4): 525-536. 10.1016\/j.beha.2005.01.006.","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"1997_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/BF02983377","volume":"78","author":"B Klein","year":"2003","unstructured":"Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, Legouffe E, De Vos J, Rossi JF: Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003, 78 (2): 106-113. 10.1007\/BF02983377.","journal-title":"Int J Hematol"},{"key":"1997_CR4","first-page":"83","volume-title":"Autocrine generation and essential requirement of BSF-2\/IL-6 for human multiple myeloma","author":"M Kawano","year":"1988","unstructured":"Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoka H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T: Autocrine generation and essential requirement of BSF-2\/IL-6 for human multiple myeloma. 1988, 332: 83-85."},{"issue":"2","key":"1997_CR5","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V73.2.517.517","volume":"73","author":"B Klein","year":"1989","unstructured":"Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, Aarden L, Piechaczyk M, Bataille R: Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989, 73 (2): 517-526.","journal-title":"Blood"},{"key":"1997_CR6","first-page":"1373","volume-title":"Interleukin-6 dependence of advanced malignant plasma cell dyscrasias","author":"XG Zhang","year":"1992","unstructured":"Zhang XG, Bataille R, Widjenes J, Klein B: Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. 1992, 69 (6): 1373-1376."},{"key":"1997_CR7","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1182\/blood.V88.6.2250.bloodjournal8862250","volume":"88","author":"P Georgii-Hemming","year":"1996","unstructured":"Georgii-Hemming P, Wiklund HJ, Ljunggren O, Nilsson K: Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines. Blood. 1996, 88: 2250-2258.","journal-title":"Blood"},{"key":"1997_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1111\/j.0105-2896.2006.00362.x","volume":"210","author":"J De Vos","year":"2006","unstructured":"De Vos J, Hose D, Reme T, Tarte K, Moreaux J, Mahtouk K, Jourdan M, Goldschmidt H, Rossi JF, Cremer FW, Klein B: Microarray-based understanding of normal and malignant plasma cells. Immunol Rev. 2006, 210: 86-104. 10.1111\/j.0105-2896.2006.00362.x.","journal-title":"Immunol Rev"},{"issue":"3","key":"1997_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1182\/blood-2004-11-4512","volume":"106","author":"J Moreaux","year":"2005","unstructured":"Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, Pantesco V, De Vos J, Jourdan E, Jauch A, Legouffe E, Moos M, Fiol G, Goldschmidt H, Rossi JF, Hose D, Klein B: The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 2005, 106 (3): 1021-1030. 10.1182\/blood-2004-11-4512.","journal-title":"Blood"},{"issue":"4","key":"1997_CR10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.V100.4.1113.h81602001113_1113_1122","volume":"100","author":"K Tarte","year":"2002","unstructured":"Tarte K, De Vos J, Thykjaer T, Zhan F, Fiol G, Costes V, Reme T, Legouffe E, Rossi JF, Shaughnessy J, Orntoft TF, Klein B: Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood. 2002, 100 (4): 1113-1122.","journal-title":"Blood"},{"issue":"25","key":"1997_CR11","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.1182\/blood-2009-07-235960","volume":"114","author":"M Jourdan","year":"2009","unstructured":"Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C, Bret C, Duperray C, Hose D, Klein B: An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood. 2009, 114 (25): 5173-5181. 10.1182\/blood-2009-07-235960.","journal-title":"Blood"},{"key":"1997_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1471-2105-9-16","volume":"9","author":"T Reme","year":"2008","unstructured":"Reme T, Hose D, De Vos J, Vassal A, Poulain PO, Pantesco V, Goldschmidt H, Klein B: A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics. 2008, 9: 16-10.1186\/1471-2105-9-16.","journal-title":"BMC Bioinformatics"},{"key":"1997_CR13","volume-title":"Stem Cells","author":"S Assou","year":"2007","unstructured":"Assou S, Lecarrour T, Tondeur S, Strom S, Gabelle A, Marty S, Nadal L, Pantesco V, Reme T, Hugnot JP, Gasca S, Hovatta O, Hamamah S, Klein B, De Vos J: A meta-analysis of human embryonic stem cells transcriptome integrated into a web-based expression atlas. Stem Cells. 2007"},{"issue":"6","key":"1997_CR14","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD: The molecular classification of multiple myeloma. Blood. 2006, 108 (6): 2020-2028. 10.1182\/blood-2005-11-013458.","journal-title":"Blood"},{"issue":"4","key":"1997_CR15","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan F, Barlogie B, Arzoumanian V, Huang Y, Williams DR, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Zangari M, Dhodapkar M, Shaughnessy JD: Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood. 2007, 109 (4): 1692-1700. 10.1182\/blood-2006-07-037077.","journal-title":"Blood"},{"issue":"24","key":"1997_CR16","doi-asserted-by":"publisher","first-page":"7289","DOI":"10.1158\/1078-0432.CCR-07-1758","volume":"13","author":"K Mahtouk","year":"2007","unstructured":"Mahtouk K, Hose D, De Vos J, Moreaux J, Jourdan M, Rossi JF, Reme T, Goldschmidt H, Klein B: Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications. Clin Cancer Res. 2007, 13 (24): 7289-7295. 10.1158\/1078-0432.CCR-07-1758.","journal-title":"Clin Cancer Res"},{"issue":"54","key":"1997_CR17","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1038\/sj.onc.1209699","volume":"25","author":"K Mahtouk","year":"2006","unstructured":"Mahtouk K, Cremer FW, Reme T, Jourdan M, Baudard M, Moreaux J, Requirand G, Fiol G, De Vos J, Moos M, Quittet P, Goldschmidt H, Rossi JF, Hose D, Klein B: Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma. Oncogene. 2006, 25 (54): 7180-7191. 10.1038\/sj.onc.1209699.","journal-title":"Oncogene"},{"issue":"4","key":"1997_CR18","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1046\/j.1365-2141.1998.01101.x","volume":"103","author":"V Costes","year":"1998","unstructured":"Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B: Interleukin-1 in multiple myeloma: producer cells and their role in the control of IL-6 production. Br J Haematol. 1998, 103 (4): 1152-1160. 10.1046\/j.1365-2141.1998.01101.x.","journal-title":"Br J Haematol"},{"issue":"1","key":"1997_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/sj.leu.2401632","volume":"14","author":"ZJ Gu","year":"2000","unstructured":"Gu ZJ, De Vos J, Rebouissou C, Jourdan M, Zhang XG, Rossi JF, Wijdenes J, Klein B: Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia. 2000, 14 (1): 188-197. 10.1038\/sj.leu.2401632.","journal-title":"Leukemia"},{"issue":"6","key":"1997_CR20","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.immuni.2004.05.001","volume":"20","author":"K Tokoyoda","year":"2004","unstructured":"Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T: Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity. 2004, 20 (6): 707-718. 10.1016\/j.immuni.2004.05.001.","journal-title":"Immunity"},{"issue":"12","key":"1997_CR21","doi-asserted-by":"publisher","first-page":"3712","DOI":"10.1182\/blood-2004-04-1670","volume":"104","author":"M Chatterjee","year":"2004","unstructured":"Chatterjee M, Stuhmer T, Herrmann P, Bommert K, Dorken B, Bargou RC: Combined disruption of both the MEK\/ERK and the IL-6R\/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood. 2004, 104 (12): 3712-3721. 10.1182\/blood-2004-04-1670.","journal-title":"Blood"},{"issue":"2","key":"1997_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1046\/j.1365-2141.2002.03257.x","volume":"116","author":"S Yaccoby","year":"2002","unstructured":"Yaccoby S, Pearse RN, Johnson CL, Barlogie B, Choi Y, Epstein J: Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol. 2002, 116 (2): 278-290. 10.1046\/j.1365-2141.2002.03257.x.","journal-title":"Br J Haematol"},{"issue":"1","key":"1997_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.coi.2006.11.004","volume":"19","author":"W Cao","year":"2007","unstructured":"Cao W, Liu YJ: Innate immune functions of plasmacytoid dendritic cells. Curr Opin Immunol. 2007, 19 (1): 24-30. 10.1016\/j.coi.2006.11.004.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"1997_CR24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","volume":"21","author":"J Corre","year":"2007","unstructured":"Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, Danho C, Laharrague P, Klein B, Reme T, Bourin P: Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia. 2007, 21 (5): 1079-1088.","journal-title":"Leukemia"},{"issue":"10","key":"1997_CR25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri1886","volume":"6","author":"A Radbruch","year":"2006","unstructured":"Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dorner T, Hiepe F: Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol. 2006, 6 (10): 741-750. 10.1038\/nri1886.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"1997_CR26","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.4049\/jimmunol.171.4.1684","volume":"171","author":"G Cassese","year":"2003","unstructured":"Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, Muehlinghaus G, Szyska M, Radbruch A, Manz RA: Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol. 2003, 171 (4): 1684-1690.","journal-title":"J Immunol"},{"issue":"1","key":"1997_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O'Connor","year":"2004","unstructured":"O'Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ: BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004, 199 (1): 91-98. 10.1084\/jem.20031330.","journal-title":"J Exp Med"},{"issue":"21","key":"1997_CR28","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1038\/sj.onc.1208536","volume":"24","author":"K Mahtouk","year":"2005","unstructured":"Mahtouk K, Hose D, Reme T, De Vos J, Jourdan M, Moreaux J, Fiol G, Raab M, Jourdan E, Grau V, Moos M, Goldschmidt H, Baudard M, Rossi JF, Cremer FW, Klein B: Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells. Oncogene. 2005, 24 (21): 3512-3524. 10.1038\/sj.onc.1208536.","journal-title":"Oncogene"},{"issue":"2","key":"1997_CR29","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood.V97.2.483","volume":"97","author":"MA Frassanito","year":"2001","unstructured":"Frassanito MA, Cusmai A, Iodice G, Dammacco F: Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood. 2001, 97 (2): 483-489. 10.1182\/blood.V97.2.483.","journal-title":"Blood"},{"issue":"12","key":"1997_CR30","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1182\/blood.V82.12.3712.3712","volume":"82","author":"H Uchiyama","year":"1993","unstructured":"Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC: Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993, 82 (12): 3712-3720.","journal-title":"Blood"},{"issue":"8","key":"1997_CR31","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","volume":"95","author":"B Dankbar","year":"2000","unstructured":"Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM, Serve H, Berdel WE, Kienast J: Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000, 95 (8): 2630-2636.","journal-title":"Blood"},{"issue":"7","key":"1997_CR32","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1182\/blood-2002-09-2907","volume":"101","author":"G Bisping","year":"2003","unstructured":"Bisping G, Leo R, Wenning D, Dankbar B, Padro T, Kropff M, Scheffold C, Kroger M, Mesters RM, Berdel WE, Kienast J: Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood. 2003, 101 (7): 2775-2783. 10.1182\/blood-2002-09-2907.","journal-title":"Blood"},{"issue":"1","key":"1997_CR33","first-page":"57","volume":"16","author":"M Jourdan","year":"2005","unstructured":"Jourdan M, Mahtouk K, Veyrune JL, Couderc G, Fiol G, Redal N, Duperray C, De Vos J, Klein B: Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. Eur Cytokine Netw. 2005, 16 (1): 57-64.","journal-title":"Eur Cytokine Netw"},{"key":"1997_CR34","first-page":"3357","volume-title":"Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells","author":"H Hata","year":"1993","unstructured":"Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J: Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. 1993, 81: 3357-3364."},{"key":"1997_CR35","volume-title":"Blood","author":"AC Sprynski","year":"2009","unstructured":"Sprynski AC, Hose D, Caillot L, Reme T, Shaughnessy JD, Barlogie B, Seckinger A, Moreaux J, Hundemer M, Jourdan M, Meissner T, Jauch A, Mahtouk K, Kassambara A, Bertsch U, Rossi JF, Goldschmidt H, Klein B: The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood. 2009"},{"issue":"2","key":"1997_CR36","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1046\/j.1365-2141.2000.02364.x","volume":"111","author":"M Ferlin","year":"2000","unstructured":"Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B: Insulin-like growth factor induces the survival and proliferation of myeloma cells through an IL-6-independent transduction pathway. Br J Haematol. 2000, 111 (2): 626-634. 10.1046\/j.1365-2141.2000.02364.x.","journal-title":"Br J Haematol"},{"key":"1997_CR37","volume-title":"Blood","author":"E Menu","year":"2005","unstructured":"Menu E, Jernberg Wiklund H, Stromberg T, De Raeve H, Girnita L, Larsson O, Axelson M, Asosingh K, Nilsson K, Van Camp B, Vanderkerken K: Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33 MM mouse model. Blood. 2005"},{"issue":"2","key":"1997_CR38","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1182\/blood-2005-01-0306","volume":"107","author":"T Stromberg","year":"2006","unstructured":"Stromberg T, Ekman S, Girnita L, Dimberg LY, Larsson O, Axelson M, Lennartsson J, Hellman U, Carlson K, Osterborg A, Vanderkerken K, Nilsson K, Jernberg-Wiklund H: IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2\/M-phase accumulation and apoptosis in multiple myeloma cells. Blood. 2006, 107 (2): 669-678. 10.1182\/blood-2005-01-0306.","journal-title":"Blood"},{"issue":"6","key":"1997_CR39","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.4049\/jimmunol.177.6.4218","volume":"177","author":"G Descamps","year":"2006","unstructured":"Descamps G, Wuilleme-Toumi S, Trichet V, Venot C, Debussche L, Hercend T, Collette M, Robillard N, Bataille R, Amiot M: CD45neg but not CD45pos human myeloma cells are sensitive to the inhibition of IGF-1 signaling by a murine anti-IGF-1R monoclonal antibody, mAVE1642. J Immunol. 2006, 177 (6): 4218-4223.","journal-title":"J Immunol"},{"issue":"2","key":"1997_CR40","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1172\/JCI115327","volume":"88","author":"SL Abboud","year":"1991","unstructured":"Abboud SL, Bethel CR, Aron DC: Secretion of insulinlike growth factor I and insulinlike growth factor-binding proteins by murine bone marrow stromal cells. J Clin Invest. 1991, 88 (2): 470-475. 10.1172\/JCI115327.","journal-title":"J Clin Invest"},{"key":"1997_CR41","first-page":"3998","volume-title":"Hepatocyte growth factor and its receptor c-met in multiple myeloma","author":"M Borset","year":"1996","unstructured":"Borset M, Hjorth-Hansen H, Seidel C, Sundan A, Waage A: Hepatocyte growth factor and its receptor c-met in multiple myeloma. 1996, 88: 3998-4004."},{"issue":"4","key":"1997_CR42","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1182\/blood.V99.4.1405","volume":"99","author":"PW Derksen","year":"2002","unstructured":"Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST: Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood. 2002, 99 (4): 1405-1410. 10.1182\/blood.V99.4.1405.","journal-title":"Blood"},{"issue":"19","key":"1997_CR43","doi-asserted-by":"publisher","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-04-0874","volume":"10","author":"H Hov","year":"2004","unstructured":"Hov H, Holt RU, Ro TB, Fagerli UM, Hjorth-Hansen H, Baykov V, Christensen JG, Waage A, Sundan A, Borset M: A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res. 2004, 10 (19): 6686-6694. 10.1158\/1078-0432.CCR-04-0874.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"1997_CR44","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1182\/blood-2006-02-003103","volume":"109","author":"W Du","year":"2007","unstructured":"Du W, Hattori Y, Yamada T, Matsumoto K, Nakamura T, Sagawa M, Otsuki T, Niikura T, Nukiwa T, Ikeda Y: NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood. 2007, 109 (7): 3042-3049.","journal-title":"Blood"},{"issue":"3","key":"1997_CR45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V91.3.806","volume":"91","author":"C Seidel","year":"1998","unstructured":"Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A: Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood. 1998, 91 (3): 806-812.","journal-title":"Blood"},{"issue":"4","key":"1997_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/ajh.10304","volume":"72","author":"MG Alexandrakis","year":"2003","unstructured":"Alexandrakis MG, Passam FH, Sfiridaki A, Kandidaki E, Roussou P, Kyriakou DS: Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am J Hematol. 2003, 72 (4): 229-233. 10.1002\/ajh.10304.","journal-title":"Am J Hematol"},{"issue":"10","key":"1997_CR47","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/sj.onc.1206239","volume":"22","author":"YW Qiang","year":"2003","unstructured":"Qiang YW, Endo Y, Rubin JS, Rudikoff S: Wnt signaling in B-cell neoplasia. Oncogene. 2003, 22 (10): 1536-1545. 10.1038\/sj.onc.1206239.","journal-title":"Oncogene"},{"issue":"16","key":"1997_CR48","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.1073\/pnas.0305855101","volume":"101","author":"PW Derksen","year":"2004","unstructured":"Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, Neut van der R, Spaargaren M, Pals ST: Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA. 2004, 101 (16): 6122-6127. 10.1073\/pnas.0305855101.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1997_CR49","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1182\/blood-2005-01-0049","volume":"106","author":"YW Qiang","year":"2005","unstructured":"Qiang YW, Walsh K, Yao L, Kedei N, Blumberg PM, Rubin JS, Shaughnessy J, Rudikoff S: Wnts induce migration and invasion of myeloma plasma cells. Blood. 2005, 106 (5): 1786-1793. 10.1182\/blood-2005-01-0049.","journal-title":"Blood"},{"issue":"26","key":"1997_CR50","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, Shaughnessy JD: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003, 349 (26): 2483-2494. 10.1056\/NEJMoa030847.","journal-title":"N Engl J Med"},{"issue":"8","key":"1997_CR51","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2003-06-1883","volume":"102","author":"S Colla","year":"2003","unstructured":"Colla S, Morandi F, Lazzaretti M, Polistena P, Svaldi M, Coser P, Bonomini S, Hojden M, Martella E, Chisesi T, Rizzoli V, Giuliani N: Do human myeloma cells directly produce basic FGF?. Blood. 2003, 102 (8): 3071-3072. 10.1182\/blood-2003-06-1883. author reply 3072-3073","journal-title":"Blood"},{"issue":"6","key":"1997_CR52","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1038\/sj.leu.2404202","volume":"20","author":"P Krejci","year":"2006","unstructured":"Krejci P, Mekikian PB, Wilcox WR: The fibroblast growth factors in multiple myeloma. Leukemia. 2006, 20 (6): 1165-1168. 10.1038\/sj.leu.2404202.","journal-title":"Leukemia"},{"issue":"9","key":"1997_CR53","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","volume":"101","author":"S Lentzsch","year":"2003","unstructured":"Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY: Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood. 2003, 101 (9): 3568-3573. 10.1182\/blood-2002-08-2383.","journal-title":"Blood"},{"issue":"12","key":"1997_CR54","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1172\/JCI200113116","volume":"108","author":"SJ Choi","year":"2001","unstructured":"Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman GD: Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest. 2001, 108 (12): 1833-1841.","journal-title":"J Clin Invest"},{"issue":"1","key":"1997_CR55","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","volume":"102","author":"BO Oyajobi","year":"2003","unstructured":"Oyajobi BO, Franchin G, Williams PJ, Pulkrabek D, Gupta A, Munoz S, Grubbs B, Zhao M, Chen D, Sherry B, Mundy GR: Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood. 2003, 102 (1): 311-319. 10.1182\/blood-2002-12-3905.","journal-title":"Blood"},{"issue":"10","key":"1997_CR56","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2007-05-093294","volume":"110","author":"S Vallet","year":"2007","unstructured":"Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson KC: MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood. 2007, 110 (10): 3744-3752. 10.1182\/blood-2007-05-093294.","journal-title":"Blood"},{"issue":"5","key":"1997_CR57","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1365-2141.2006.06052.x","volume":"133","author":"HS Yeh","year":"2006","unstructured":"Yeh HS, Chen H, Manyak SJ, Swift RA, Campbell RA, Wang C, Li M, Lee HJ, Waterman G, Gordon MS, Ma J, Bonavida B, Berenson JR: Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status. Br J Haematol. 2006, 133 (5): 526-529. 10.1111\/j.1365-2141.2006.06052.x.","journal-title":"Br J Haematol"},{"issue":"1","key":"1997_CR58","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1182\/blood-2006-08-042374","volume":"110","author":"H Chen","year":"2007","unstructured":"Chen H, Gordon MS, Campbell RA, Li M, Wang CS, Lee HJ, Sanchez E, Manyak SJ, Gui D, Shalitin D, Said J, Chang Y, Deuel TF, Baritaki S, Bonavida B, Berenson JR: Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. Blood. 2007, 110 (1): 287-295. 10.1182\/blood-2006-08-042374.","journal-title":"Blood"},{"issue":"11","key":"1997_CR59","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1182\/blood-2004-08-3096","volume":"105","author":"RN Pearse","year":"2005","unstructured":"Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL: A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood. 2005, 105 (11): 4429-4436. 10.1182\/blood-2004-08-3096.","journal-title":"Blood"},{"issue":"12","key":"1997_CR60","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1182\/blood.V83.12.3654.3654","volume":"83","author":"XG Zhang","year":"1994","unstructured":"Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, Boiron JM, Bataille R, Klein B: Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994, 83 (12): 3654-3663.","journal-title":"Blood"},{"issue":"12","key":"1997_CR61","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1038\/sj.cdd.4400758","volume":"7","author":"M Jourdan","year":"2000","unstructured":"Jourdan M, De Vos J, Mechti N, Klein B: Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ. 2000, 7 (12): 1244-1252. 10.1038\/sj.cdd.4400758.","journal-title":"Cell Death Differ"},{"issue":"6","key":"1997_CR62","first-page":"2008","volume":"84","author":"R Bataille","year":"1989","unstructured":"Bataille R, Jourdan M, Zhang XG, Klein B: Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. JClinInvest. 1989, 84 (6): 2008-2011.","journal-title":"JClinInvest"},{"issue":"4","key":"1997_CR63","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1002\/eji.1830230408","volume":"23","author":"JP Gaillard","year":"1993","unstructured":"Gaillard JP, Bataille R, Brailly H, Zuber C, Yasukawa K, Attal M, Maruo N, Taga T, Kishimoto T, Klein B: Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. Eur J Immunol. 1993, 23 (4): 820-824. 10.1002\/eji.1830230408.","journal-title":"Eur J Immunol"},{"key":"1997_CR64","first-page":"2794","volume-title":"Interleukin-6 is a prognostic factor in multiple myeloma","author":"H Ludwig","year":"1991","unstructured":"Ludwig H, Nachbaur DM, Fritz E, Krainer M, Huber H: Interleukin-6 is a prognostic factor in multiple myeloma. 1991, 77: 2794-2795."},{"issue":"5","key":"1997_CR65","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1182\/blood.V78.5.1198.1198","volume":"78","author":"B Klein","year":"1991","unstructured":"Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J, Liautard J, Merlin M, Clement C, Morel-Fournier B: Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991, 78 (5): 1198-1204.","journal-title":"Blood"},{"issue":"2","key":"1997_CR66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.V86.2.685.bloodjournal862685","volume":"86","author":"R Bataille","year":"1995","unstructured":"Bataille R, Barlogie B, Lu ZY, Rossi JF, Lavabre-Bertrand T, Beck T, Wijdenes J, Brochier J, Klein B: Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995, 86 (2): 685-691.","journal-title":"Blood"},{"issue":"9","key":"1997_CR67","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/sj.bmt.1705138","volume":"36","author":"JF Rossi","year":"2005","unstructured":"Rossi JF, Fegueux N, Lu ZY, Legouffe E, Exbrayat C, Bozonnat MC, Navarro R, Lopez E, Quittet P, Daures JP, Rouille V, Kanouni T, Widjenes J, Klein B: Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg\/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant. 2005, 36 (9): 771-779. 10.1038\/sj.bmt.1705138.","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"1997_CR68","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1158\/1078-0432.CCR-07-1293","volume":"13","author":"PM Voorhees","year":"2007","unstructured":"Voorhees PM, Chen Q, Kuhn DJ, Small GW, Hunsucker SA, Strader JS, Corringham RE, Zaki MH, Nemeth JA, Orlowski RZ: Inhibition of Interleukin-6 Signaling with CNTO 328 Enhances the Activity of Bortezomib in Preclinical Models of Multiple Myeloma. Clin Cancer Res. 2007, 13 (21): 6469-6478. 10.1158\/1078-0432.CCR-07-1293.","journal-title":"Clin Cancer Res"},{"key":"1997_CR69","first-page":"21","volume-title":"Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M","author":"ZJ Gu","year":"1996","unstructured":"Gu ZJ, Wijdenes J, Zhang XG, Hallet MM, Clement C, Klein B: Anti-gp130 transducer monoclonal antibodies specifically inhibiting ciliary neurotrophic factor, interleukin-6, interleukin-11, leukemia inhibitory factor or oncostatin M. 1996, 190 (1): 21-27."},{"issue":"5","key":"1997_CR70","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1046\/j.1365-2141.2003.04686.x","volume":"123","author":"R Burger","year":"2003","unstructured":"Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, Tai YT, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson KC: Functional significance of novel neurotrophin-1\/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Br J Haematol. 2003, 123 (5): 869-878. 10.1046\/j.1365-2141.2003.04686.x.","journal-title":"Br J Haematol"},{"issue":"9","key":"1997_CR71","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1182\/blood.V85.9.2521.bloodjournal8592521","volume":"85","author":"ZY Lu","year":"1995","unstructured":"Lu ZY, Zhang XG, Rodriguez C, Wijdenes J, Gu ZJ, Morel-Fournier B, Harousseau JL, Bataille R, Rossi JF, Klein B: Interleukin-10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood. 1995, 85 (9): 2521-2527.","journal-title":"Blood"},{"issue":"10","key":"1997_CR72","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1182\/blood.V88.10.3972.bloodjournal88103972","volume":"88","author":"ZJ Gu","year":"1996","unstructured":"Gu ZJ, Costes V, Lu ZY, Zhang XG, Pitard V, Moreau JF, Bataille R, Wijdenes J, Rossi JF, Klein B: Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood. 1996, 88 (10): 3972-3986.","journal-title":"Blood"},{"issue":"2","key":"1997_CR73","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1182\/blood.V95.2.610","volume":"95","author":"I Tinhofer","year":"2000","unstructured":"Tinhofer I, Marschitz I, Henn T, Egle A, Greil R: Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma. Blood. 2000, 95 (2): 610-618.","journal-title":"Blood"},{"issue":"10","key":"1997_CR74","doi-asserted-by":"publisher","first-page":"3756","DOI":"10.1182\/blood.V99.10.3756","volume":"99","author":"AT Brenne","year":"2002","unstructured":"Brenne AT, Baade Ro T, Waage A, Sundan A, Borset M, Hjorth-Hansen H: Interleukin-21 is a growth and survival factor for human myeloma cells. Blood. 2002, 99 (10): 3756-3762. 10.1182\/blood.V99.10.3756.","journal-title":"Blood"},{"issue":"1","key":"1997_CR75","first-page":"65","volume":"10","author":"M Jourdan","year":"1999","unstructured":"Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, Klein B: Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw. 1999, 10 (1): 65-70.","journal-title":"Eur Cytokine Netw"},{"issue":"33","key":"1997_CR76","doi-asserted-by":"publisher","first-page":"4519","DOI":"10.1038\/sj.onc.1204623","volume":"20","author":"T Hideshima","year":"2001","unstructured":"Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC: The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001, 20 (33): 4519-4527. 10.1038\/sj.onc.1204623.","journal-title":"Oncogene"},{"issue":"4","key":"1997_CR77","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2141.1990.tb06330.x","volume":"74","author":"A Carter","year":"1990","unstructured":"Carter A, Merchav S, Silvian-Draxler I, Tatarsky I: The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br J Haematol. 1990, 74 (4): 424-431. 10.1111\/j.1365-2141.1990.tb06330.x.","journal-title":"Br J Haematol"},{"issue":"1","key":"1997_CR78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1600-0609.1994.tb00176.x","volume":"53","author":"M Borset","year":"1994","unstructured":"Borset M, Waage A, Brekke OL, Helseth E: TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line. Eur J Haematol. 1994, 53 (1): 31-37. 10.1111\/j.1600-0609.1994.tb00176.x.","journal-title":"Eur J Haematol"},{"issue":"8","key":"1997_CR79","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","volume":"103","author":"J Moreaux","year":"2004","unstructured":"Moreaux J, Legouffe E, Jourdan E, Quittet P, Reme T, Lugagne C, Moine P, Rossi JF, Klein B, Tarte K: BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004, 103 (8): 3148-3157. 10.1182\/blood-2003-06-1984.","journal-title":"Blood"},{"issue":"2","key":"1997_CR80","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF: Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004, 103 (2): 689-694. 10.1182\/blood-2003-06-2043.","journal-title":"Blood"},{"issue":"7","key":"1997_CR81","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/sj.leu.2404228","volume":"20","author":"M Abe","year":"2006","unstructured":"Abe M, Kido S, Hiasa M, Nakano A, Oda A, Amou H, Matsumoto T: BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma. Leukemia. 2006, 20 (7): 1313-1315. 10.1038\/sj.leu.2404228.","journal-title":"Leukemia"},{"key":"1997_CR82","volume-title":"Leukemia","author":"S Yaccoby","year":"2007","unstructured":"Yaccoby S, Pennisi A, Li X, Dillon SR, Zhan F, Barlogie B, Shaughnessy JD: Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts. Leukemia. 2007"},{"issue":"16","key":"1997_CR83","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1038\/sj.onc.1205355","volume":"21","author":"YD Wang","year":"2002","unstructured":"Wang YD, De Vos J, Jourdan M, Couderc G, Lu ZY, Rossi JF, Klein B: Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene. 2002, 21 (16): 2584-2592. 10.1038\/sj.onc.1205355.","journal-title":"Oncogene"},{"issue":"5","key":"1997_CR84","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1182\/blood-2003-05-1510","volume":"103","author":"K Mahtouk","year":"2004","unstructured":"Mahtouk K, Jourdan M, De Vos J, Hertogh C, Fiol G, Jourdan E, Rossi JF, Klein B: An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood. 2004, 103 (5): 1829-1837. 10.1182\/blood-2003-05-1510.","journal-title":"Blood"},{"issue":"9","key":"1997_CR85","doi-asserted-by":"publisher","first-page":"3511","DOI":"10.1182\/blood-2003-07-2254","volume":"103","author":"F Jundt","year":"2004","unstructured":"Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S, Bargou RC, Manz R, Stein H, Dorken B: Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood. 2004, 103 (9): 3511-3515. 10.1182\/blood-2003-07-2254.","journal-title":"Blood"},{"issue":"12","key":"1997_CR86","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1182\/blood-2003-12-4114","volume":"104","author":"C Houde","year":"2004","unstructured":"Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J, Nand S, Toor A, Alkan S, Smadja NV, Avet-Loiseau H, Lima CS, Miele L, Coignet LJ: Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood. 2004, 104 (12): 3697-3704. 10.1182\/blood-2003-12-4114.","journal-title":"Blood"},{"issue":"9","key":"1997_CR87","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood-2003-07-2340","volume":"103","author":"Y Nefedova","year":"2004","unstructured":"Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI: Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004, 103 (9): 3503-3510. 10.1182\/blood-2003-07-2340.","journal-title":"Blood"},{"key":"1997_CR88","volume-title":"Blood","author":"Y Nefedova","year":"2007","unstructured":"Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI: Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2007"},{"issue":"2","key":"1997_CR89","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1182\/blood.V98.2.428","volume":"98","author":"K Podar","year":"2001","unstructured":"Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC: Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001, 98 (2): 428-435. 10.1182\/blood.V98.2.428.","journal-title":"Blood"},{"issue":"10","key":"1997_CR90","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/sj.leu.2403084","volume":"17","author":"S Kumar","year":"2003","unstructured":"Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R, Greipp PR, Rajkumar SV: Expression of VEGF and its receptors by myeloma cells. Leukemia. 2003, 17 (10): 2025-2031. 10.1038\/sj.leu.2403084.","journal-title":"Leukemia"},{"issue":"9","key":"1997_CR91","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/blood-2004-05-1760","volume":"104","author":"S Le Gouill","year":"2004","unstructured":"Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K, Kumar S, Raje N, Richardson PG, Harousseau JL, Anderson KC: VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood. 2004, 104 (9): 2886-2892. 10.1182\/blood-2004-05-1760.","journal-title":"Blood"},{"issue":"51","key":"1997_CR92","doi-asserted-by":"publisher","first-page":"19478","DOI":"10.1073\/pnas.0609329103","volume":"103","author":"K Podar","year":"2006","unstructured":"Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC: The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA. 2006, 103 (51): 19478-19483. 10.1073\/pnas.0609329103.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-10-198\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-10-198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:02:00Z","timestamp":1630530120000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-10-198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,13]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["1997"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-10-198","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,13]]},"assertion":[{"value":"6 November 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"198"}}